-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompileKe Ke
Recently, foreign media reported that the National Institute of Health Care Excellence (NICE) recommended AstraZeneca/Mersk’s Lynparza (Olabarib) and Roche’s Avastin (bevacizumab) through the Cancer Drug Fund (CDF).
This recommendation is based on data from the phase 3 clinical study PAOLA-1.
In this study, about 48% of patients were newly diagnosed patients with HRD-positive advanced ovarian cancer.
The British National Health System (NHS) supports the introduction of olaparib combined with bevacizumab therapy, and the organization is providing genomic HRD testing for patients who use the therapy for the first time.
Olabarib is known as a PARP inhibitor as an inhibitor of poly ADP ribose polymerase (PARP).
In December 2014, the European Medicines Agency (EMA) and the U.
Reference source:
1.
2.